RPH-051
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RPH-051, covering 2026-02-04 to 2026-02-04. Get the full timeline:
Most recent: Clinical Trial Update: A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer [Phase 3]